{"id":86412,"date":"2026-05-13T12:34:09","date_gmt":"2026-05-13T07:04:09","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=86412"},"modified":"2026-05-13T12:34:10","modified_gmt":"2026-05-13T07:04:10","slug":"dr-reddys-q4-fy26-results-pat-rs-221-crore-down-86-percent","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/dr-reddys-q4-fy26-results-pat-rs-221-crore-down-86-percent\/","title":{"rendered":"Dr Reddy’s Laboratories Q4 FY26 Results: PAT Rs 221 Crore Down 86 Percent YoY on One-Off Charges and Lower US Sales"},"content":{"rendered":"
\n

Dr Reddy’s <\/a><\/strong>Q4 FY26 results were announced by Dr Reddy’s Laboratories Limited on 12 May 2026, with the Hyderabad-based pharmaceutical major reporting a consolidated net profit of Rs 221.3 crore for the quarter ended March 31, 2026, an 86.05 percent year-on-year decline from Rs 1,586.7 crore in Q4 FY25. The <\/span>Dr Reddy’s Q4 FY26<\/strong> profit collapse was primarily driven by a shelf stock adjustment of Rs 453 crore related to lenalidomide taken as a reduction in revenue, discontinuation of CAR-T therapy R&D programs resulting in a net impairment charge of Rs 135 crore, and an additional VAT liability provision of Rs 69.5 crore. Revenue from operations declined 11.51 percent year-on-year to Rs 7,546.4 crore from Rs 8,528.4 crore in Q4 FY25.<\/span><\/p>\n<\/div>\n

Click Here \u2013 Get Free Investment Predictions<\/a><\/p>\n

The board of Dr Reddy’s Laboratories recommended a final dividend of Rs 8 per equity share of face value Re 1 each for FY26, representing an 800 percent payout on face value. The record date for determining eligible shareholders for the dividend was fixed as July 10, 2026. Co-Chairman and Managing Director G V Prasad commented that the company’s performance in FY26 reflects the impact of lower lenalidomide sales and several one-off charges, adding that the resilience of branded businesses and currency tailwinds helped partially mitigate the impact.<\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n